Olanzapine (zyprexa) 5 mg tablet

A governmentally-recognized ID which uniquely identifies the product within its regulatory market. Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes. Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults. As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old. Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.

It's also used to treat depression when used olanzapine (zyprexa) 5 mg tablet other medications. By taking this drug you may be able to decrease hallucinations, reduce feelings of agitation, and think more clearly and positively. This medication is also used for preventing chemotherapy-induced nausea and vomiting. Unless directed by your doctor, never use Zyprexa for off-label use. In, the FDA approved Zyprexa Relprevv extended-release injectable suspension to treat adults with schizophrenia.

Zyprexa olanzapine is an antipsychotic medication that affects chemicals in the brain. Zyprexa is used to treat the symptoms of psychotic conditions such as schizophrenia and the symptoms of mood disorders such as bipolar disorder manic depression in adults and children who are at least 13 olanzapine (zyprexa) 5 mg tablets old. Zyprexa may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. You may gain weight or have high cholesterol and triglycerides types of fat while taking this medicine, especially if you are a teenager.

Olanzapine is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder manic depression in adults and children who are at least 13 years old. Olanzapine is sometimes used together with other antipsychotic medications or antidepressants. Long-term use of olanzapine can cause a serious movement disorder that may not be reversible.

Olanzapine is used to treat nervous, emotional, and mental conditions eg, schizophrenia. It may also be used alone or olanzapine (zyprexa) 5 mg tablet other medicines eg, lithium or valproate to treat bipolar disorder manic-depressive illness or mania that is part of bipolar disorder. This medicine should not be used to treat behavioral problems in older adult patients who have dementia or Alzheimer's disease.

ZYPREXA VELOTAB 5 mg, 10 mg, 15 mg, and 20 mg orodispersible tablet is a yellow, round, freeze-dried, rapid-dispersing preparation to be placed in the mouth or alternatively to be dispersed in water or other suitable beverage for administration. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder see section 5. Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy see section 5. For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose. An increase to a dose greater than the recommended starting dose is advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours.

[PUNIQRANDLINE-(phpdilute_eng_full/olanzapine (zyprexa) 5 mg tablet.txt)]

Older adults with dementia may also have a greater chance of having a stroke or mini-stroke during treatment. Olanzapine is not approved by the Food and Drug Administration FDA for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is taking olanzapine.

[PUNIQRANDLINE-(phpdilute_eng_full/olanzapine (zyprexa) 5 mg tablet.txt)]

In addition, a Single Photon Emission Computed Tomography SPECT imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D 2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients. In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium divalproex in reduction of manic symptoms over 3 weeks.

In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition of olanzapine 10 mg co-therapy with lithium or valproate resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks. Controlled efficacy data in adolescents ages 13 to 17 years are limited to short term studies in schizophrenia 6 weeks and mania associated with bipolar I disorder 3 weeks, involving less than adolescents.

Olanzapine was used as a flexible dose starting with 2. During treatment with olanzapine, adolescents gained significantly more weight compared with adults. The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and prolactin see sections 4. There are no controlled data on maintenance of effect or long term safety see sections 4.

Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations within 5 to 8 hours. The absorption is not affected by food. Absolute oral bioavailability relative to intravenous administration has not been determined. Olanzapine is metabolised in the liver by conjugative and oxidative pathways. The major circulating metabolite is the N-glucuronide, which does not pass the blood brain barrier. The predominant pharmacologic activity is from the parent, olanzapine.

After oral administration, the mean terminal elimination half-life of olanzapine in healthy subjects varied on the basis of age and gender. In healthy elderly 65 and over versus non-elderly subjects, the mean elimination half-life was prolonged The pharmacokinetic variability observed in the elderly is within the range for the non-elderly. In female versus male subjects, the mean elimination half-life was somewhat prolonged In non-smoking versus smoking subjects males and females, the mean elimination half-life was prolonged The plasma clearance of olanzapine is lower in elderly versus young subjects, in females versus males, and in non-smokers versus smokers.

However, the magnitude of the impact of age, gender, or smoking on olanzapine clearance and half-life is small in comparison to the overall variability between individuals. In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.

Health care professionals are increasingly involved in the administration of drugs to patients, either as an exemption to the Medicines Act directions, or as supplementary prescribers. The Medicines Act secondary legislation since then, provides a legal framework for the manufacture, licensing, prescription, dispensing and administration of medicines. An exemption to the Medicines Act allows certain professionals, including podiatrists, access to specified prescription-only medicines, providing they are appropriately registered with the Health Professions Council.

[PUNIQRANDLINE-(phpdilute_eng_full/olanzapine (zyprexa) 5 mg tablet.txt)]

Venlafaxine selectively inhibits the re-uptake of both olanzapine (zyprexa) 5 mg tablet and noradrenaline. It has benefits in patients with symptoms of melancholia, anxiety or agitation. Reboxetine selectively inhibits the re-uptake of noradrenaline and is particularly useful in patients with negative symptoms such as withdrawal and flattening of emotional response. Drugs have been developed that block serotonin receptor sub-types while still enhancing serotonin transmission.

Peripheral actions include nausea, provera 20 mgs and postural hypotension, although these are lessened by the use of carbidopa. Central side effects with long-term therapy of levodopa can be serious enough for treatment to be stopped. These include dyskinesias, restlessness, anxiety, confusion, disorientation, insomnia or a schizophrenia-like syndrome.

Coagulation disorder can be secondary to liver disease because most clotting factors are synthesized in the liver. Vitamin K is essential for successful formation of many clotting factors so lack of vitamin K can cause a coagulation disorder. Normal bile acid production is necessary for absorption of vitamin K from the small intestine. Although lack of vitamin K is rare, because it is present in green leafy vegetables and synthesized by intestinal bacteria, it may occur with a combination of poor diet and long-term use of antibiotics.